UnknownNot Applicable

Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19

20 participantsStarted 2021-06

Plain-language summary

Randomized controlled trial to analyse adjuvant therapeutic plasma exchange (TPE) in severe Covid-19 associated coagulopathy and systemic inflammation compared to current standard of care (SOC). A total of three TPEs (d1, 3, 5) will be performed in the intervention group. Primary endpoint is the reversibility of relative ADAMTS13 deficiency (indicated by the change in ADAMTS13 / VWF:Ag ratio from day 1 to 7).

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Proven SARS-CoV2 infection * Severe Covid-19 (indicated by respiratory failure requiring invasive mechanical ventilation) * Evidence of coagulopathy (indicated by D-dimer \> 10 mg/L) * Evidence of systemic inflammation (CRP \> 100 mg/L , ferritin \> 500 ng/mL) Exclusion Criteria: * • Participation in another study with investigational drug within the 30 days preceding and during the present study, * Previous enrolment into the current study. * Extra corporeal membrane oxygenation (ECMO)

What they're measuring

relative ADAMTS13 deficiency

Timeframe: day 1 to 7

Trial details

NCT IDNCT04613986

SponsorUniversity of Zurich

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12

View on ClinicalTrials.gov More Severe Covid-19 trials